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Characterization of the regions of human papillomaviruses (HPVs) that elicit neutralizing immune responses supports
studies on viral infectivity and provides insight for the development and evaluation of prophylactic vaccines. HPV11 is a major
etiologic agent of genital warts and a likely vaccine candidate. A conformationally dependent epitope for the binding of three
neutralizing monoclonal antibodies (mAbs) has been mapped to residues G131T132 of the L1 major capsid protein. The mAbs
bind L1 only when it is assembled into virions or into virus-like particles (VLPs) that mimic the capsid structure. We were
interested in identifying other domains of L1 that elicit neutralizing responses. To this end, we have generated a panel of
mAbs against VLPs derived from HPV11 L1 harboring a G131S substitution. The new mAbs are unlike the neutralizing mAbs
previously mapped to residues G131T132 in that they bind both prototype and HPV11:G131S mutant VLPs. Some of the new
mAbs neutralized virus in vitro. We have mapped epitopes for three of these new mAbs, as well as a neutralizing mAb
generated against HPV11 virions, by measuring binding to HPV6 VLPs substituted with HPV11-like amino acids. Two regions
are critical: one defined by HPV11 L1 residues 263–290 and the other by residues 346–349. mAbs H11.H3 and H11.G131S.G3
bind HPV6 VLPs with substitutions derived from the 346–349 region; in addition, H11.G131S.G3 binds HPV6 VLPs with
substitutions derived only from the 263–290 region. Although H11.H3 does not bind HPV6 VLPs with substitutions derived
from the 263–290 region, binding to HPV6 VLPs is enhanced when both sets of substitutions are present. mAbs H11.G131S.I1
and H11.G131S.K5 bind HPV6 VLPs with the 263–290 substitutions, but show little binding to HPV6 VLPs with the 346–349
substitutions. However, binding to HPV6 VLPs is enhanced when substitutions at both regions are present. The 346–349
region has not previously been described as eliciting a neutralizing response for any HPV type. In addition, the work
demonstrates a complex binding site contributed by two distinct regions of L1. © 2000 Academic PressINTRODUCTION
Human papillomaviruses (HPVs) are small DNA tumor
viruses associated with a number of benign and malig-
nant epithelial lesions (reviewed in Howley, 1996). They
are encoded by an 8.0-kDa double-stranded DNA ge-
nome encapsidated in a 55-nm particle composed of
major L1 and minor L2 capsid proteins. L1, expressed
either alone or with L2, spontaneously assembles into
virus-like particles (VLPs) that morphologically and im-
munologically resemble native capsids (Hagansee et al.,
1993; Heino et al., 1996; Hofmann et al., 1995; Kirnbauer
et al., 1992; Rose et al., 1993; Xi and Banks, 1991, Zhou et
al., 1991). VLPs are useful tools to evaluate humoral
responses and to investigate early events in infectivity
(Booy et al., 1998; Christensen et al., 1995a; Roden et al.,
1996). Immunization with VLPs provides protection
against infection in bovine, canine, and rabbit model1 To whom correspondence and reprint requests should be ad-
ressed. Fax: (732) 594-5468. E-mail: steven_ludmerer@merck.com.
23systems, and VLP-based vaccines are currently being
evaluated in human clinical trials (Breitburd et al., 1995;
Christensen et al., 1995b; Jansen et al., 1995; Kirnbauer et
al., 1996; Lowy and Schiller, 1998; Suzich et al., 1995).
It is useful to define regions of VLPs that elicit neu-
tralizing responses; such mapping studies may identify
regions of viral surfaces critical for infectivity and will
also be valuable in the evaluation of human vaccines. A
number of monoclonal antibodies (mAbs) that neutralize
virus in one or more in vitro neutralization assays have
been generated (Christensen et al., 1990, 1994, 1996a,
1996c). Typically such antibodies recognize conforma-
tion-dependent epitopes and bind only native virions or
assembled VLPs (Carter et al., 1993; Christensen et al.,
1990, 1992; Christensen and Kreider, 1991; Ghim et al.,
1992; Jansen et al., 1995; Jarrett et al., 1990a, 1990b, 1991;
Steele and Gallimore, 1990). Mapping the binding site of
these mAbs will help delineate those regions of the viral
surface that elicit neutralizing responses.The first of such mapping studies showed that HPV11
binding specificity for three antibodies (H11.B2, H11.F1,
0042-6822/00 $35.00
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238 LUDMERER ET AL.and H11.G5) that neutralize this virus are conferred by L1
residues G131Y132 (Ludmerer et al., 1996, 1997). The same
tudies also demonstrated that a fourth neutralizing
Ab, H11.H3, bound a surface region different from that
ecognized by the other three mAbs, thus demonstrating
hat at least two surfaces on the particle elicit neutraliz-
ng responses. While the study did not formally map the
11.H3 binding site, a substitution at S346 adversely af-
ected its binding, suggesting that the H11.H3 binding
ite includes residue S346. Because this region had not
been implicated in any other mapping studies of HPV
neutralizing mAbs, we decided to characterize the
H11.H3 binding site.
To further increase our understanding of which re-
gions of HPV elicit neutralizing responses, we also gen-
erated a novel panel of VLP-dependent mAbs using a
mutant VLP unreactive with one set of neutralizing mAbs.
We had noted previously that a G131S substitution into
the HPV11 L1 sequence specifically abolished binding of
those mAbs mapped to G131Y132, while the binding of
ther VLP-dependent antibodies, including H11.H3, ap-
eared unperturbed (Ludmerer et al., 1996). This sug-
ested that VLP structure was not compromised by the
131S substitution and that immunization with G131S
ubstituted VLPs (HPV11:G131S VLPs), in which the
131Y132 neutralizing epitope was eliminated, may in-
crease the likelihood of generating antibodies that bind
different sites. If such antibodies also neutralize virus,
they would help define additional regions of VLPs that
elicit neutralizing responses.
In this communication we report the production of a
panel of HPV11 mAbs generated against HPV11:G131S
VLPs. We demonstrate that several of these mAbs are
both VLP-dependent and type-specific in binding, hall-
marks of important HPV mAbs. All of these mAbs bind
both HPV11 prototype and HPV11:G131S VLPs, distin-
guishing their binding from the previously mapped
HPV11 neutralizing mAbs. A subset of these mAbs neu-
tralize HPV11 and may define distinct neutralizing re-
gions of VLPs. Finally we report the mapping of three of
these mAbs, as well as the previously unmapped mAb
H11.H3, and define a novel region of HPV11 VLPs that
elicits neutralizing responses.
RESULTS
Generation of a novel panel of HPV11 mAbs by immu-
nization with HPV11:G131S VLPs. HPV11:G131S VLPs
were used as immunogen to generate a panel of mAbs.
Binding was monitored by ELISA to assess which mAbs
were VLP-dependent and HPV11-specific in binding (Ta-
ble 1). Data for 10 new mAbs are presented. Five showed
type-specific reactivity to HPV11 and HPV11:G131S VLPs;
the remainder were cross-reactive with HPV11 and HPV6
VLPs. These results are fundamentally different from
previous results immunizing with HPV11 virions, in which3 of 5 mAbs did not bind HPV11:G131S VLPs (Ludmerer
et al., 1996, 1997).
Neutralization of HPV11 infectivity by novel HPV11
mAbs. The mAbs were screened for the ability to neu-
tralize HPV11 infectivity of A431 cells (Fig. 1). Infectivity
was conducted at low viral input (5 3 105 dilution of virus
tock extract). RT-PCR was performed using primers that
pecifically amplify an E1-E4 spliced transcript (Rychlik
nd White, 1993; Smith et al., 1995). Absence of the
piced 273-bp transcript demonstrates antibody-medi-
ted neutralization of infectivity. Amplification of a 429-bp
b-actin fragment was also conducted to verify integrity of
the mRNA and for normalization.
No spliced transcript was observed when infection
was conducted in the presence of H11.B2. This mAb
previously was demonstrated to neutralize infectivity in
the athymic mouse xenograph assay and thus serves as
a control for neutralization (Christensen et al., 1990;
reider et al., 1985). Six of nine of the novel mAbs also
locked E1-E4 transcript production, indicative of neu-
ralization.
Neutralization was further evaluated in the presence
f a fivefold higher concentration (103 dilution of virus
stock extract) of HPV11 virus (Table 2). Under these more
stringent conditions, mAbs H11.G131S.G3, H11.G131S.I1,
and H11.G131S.K5 still blocked production of the E1-E4
spliced transcript. Thus H11.G131S.G3, H11.G131S.I1, and
H11.G131S.K5 are neutralizing mAbs that bind sites dis-
TABLE 1
mAbs Generated against HPV11:G131S VLPs
mAb HPV11 VLPs HPV11:G131S VLPs HPV6 VLPs
H11.A3.2 0.515 0.933 0.001
H11.B2 1.296 0.005 0.001
H11.H3 1.106 1.152 0.000
H6.C6 0.452 0.568 0.592
H6.M48 0.002 0.002 0.341
H11.G131S.A10 0.050 0.087 0.007
H11.G131S.B8 0.300 0.386 0.338
H11.G131S.C2 0.249 0.495 0.000
H11.G131S.D2 0.331 0.453 0.224
H11.G131S.E38 0.305 0.501 0.745
H11.G131S.F6 0.403 0.610 0.606
H11.G131S.G3 0.457 0.470 0.000
H11.G131S.H5 0.256 0.339 0.564
H11.G131S.I1 0.705 0.910 0.000
H11.G131S.K5 0.293 0.494 0.003
Note. 1:50 dilutions of tissue culture supernatant of mAbs generated
against HPV11:G131S VLPs were tested for binding in an ELISA to 1 mg
f cesium chloride-banded VLPs of HPV6, HPV11, and HPV11:G131S.
lkaline phosphatase-conjugated anti-mouse IgG (1:1000 dilution) was
sed as the secondary antibody, and the values shown are absor-
ances at 410 nm. H11.A3.2, H11.B2, and H11.H3 were generated
gainst HPV11 virions; H6.C6 and H6.M48 were generated against
PV6 VLPs.tinct from the previously defined neutralizing domain
centered at residues 131–132, and these three mAbs
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239NEUTRALIZING mAbs GENERATED AGAINST HPV11 MUTANT VLPswere selected for mapping. Failure of a particular super-
natant to neutralize in this assay could be due solely to
an insufficient amount of antibody in the assay (the
antibody concentrations among the tissue culture super-
natants were not normalized). This may be especially
pertinent for H11.G131S.A10, which gave a much lower
ELISA signal than any of the other mAbs (Table 1). We
FIG. 1. Neutralization of HPV11 virions in an RT-PCR infectivity assay.
he RT-PCR infectivity assay was used to assess neutralization for
everal HPV11-specific mAbs at low viral input as described in the text.
he assay detects the presence of a spliced E1-E4 transcript utilizing
rimers specific to this transcript. Infectivity is demonstrated by the
resence of a 273-bp fragment of E1-E4 cDNA; the absence of this
ragment is indicative of neutralization. H11.B2 neutralizes this virus in
he athymic xenograph assay and is included as a control for neutral-
zation. In this particular assay, six of nine mAbs generated against
PV11:G131S substituted VLPs neutralize virus as demonstrated by the
ack of production of the E1-E4 transcript. (A) PCR with E1-E4 specific
rimers. Lanes M, molecular weight markers; 1, H11.B2; 2,
11.G131S.A10; 3, H11.G131S.B8; 4, H11.G131S.C2; 5, H11.G131S.D2; 6,
11.G131S.E38; 7, H11.G131S.F6; 8, H11.G131S.G3; 9, H11.G131S.H5; 10,
11.G131S.I1; 11, A431 cells; 12, HPV11 infection without antibody. (B)
CR with b-actin-specific primers.
TABLE 2
Neutralizing Activity against HPV11 Infection in Vitro
mAb
HPV11 neutralizationa
Low viral input High viral input
11.B2 1 1
11.G131S.A10 1 2
11.G131S.B8 2 2
11.G131S.C2 1 2
11.G131S.D2 1 2
11.G131S.E38 2 2
11.G131S.F6 2 2
11.G131S.G3 1 1
11.G131S.H5 1 2
11.G131S.I1 1 1
11.G131S.K5 Not tested 1
Note. mAbs were assayed for interference of HPV11 infection of A431
ells. mAbs were incubated with HPV11 virions extracted from exper-
mental condylomas from athymic mice. Incubations were conducted at
oth low and high viral input (1:5000 and 1:1000 dilutions, respectively,
f the stock virus). Neutralization (1) was assessed by the absence of
spliced E1-E4 transcript.
a 1 indicates neutralization, as assessed by absence of the spliced
E1-E4 transcript.directed the initial mapping efforts, however, at those
three mAbs that neutralized in this assay at high viral
input.
H11.H3 and H11.G131S.G3 define a novel region of
HPV11 VLPs that elicits a neutralizing response. We fo-
cused our initial mapping studies on mAbs H11.H3 and
H11.G131S.G3. mAb H11.G131S.G3 showed one of the
strongest neutralizing activities among the new mAbs
tested, while H11.H3 neutralized infectivity in two differ-
ent infectivity assays (Christensen et al., 1990; Smith et
al., 1995). In addition, preliminary mapping studies on
H11.G131S.G3 suggested that this mAb and H11.H3
bound at or near the same region of the capsid (N. D.
Christensen, unpublished observations).
The HPV6 and HPV11 L1 sequences are closely re-
lated (.92% amino acid identity); of the 38 amino acid
differences, several are clustered in regions predicted by
hydropathy plots to be surface-exposed (Ludmerer et al.,
1996). We constructed a total of five HPV6 L1 mutants, all
of which harbor multiple, closely spaced HPV11-like sub-
stitutions (Table 3). The L1 proteins of HPV6 and HPV11
are 500 and 501 amino acids in length, respectively. To
maximize alignment, a single residue gap is introduced
into the HPV6 L1 sequence after residue 131, resulting in
38 residue differences between the aligned sequences.
This offsets numbering C-terminal to residue 131 by 1.
For example, HPV6 L1 residues 345–348 correspond to
HPV11 L1 residues 346–349. HPV6 mutant VLPs were
produced and the binding of mAbs H11.H3 and
TABLE 3
L1 Clones Expressed and Evaluated for mAb Binding
Clone Substitution
PV6 prototype None
PV11 prototype None
PV6:49–54 F49Y, R53K, A54V
PV6:169–178 K169T, T172S, P175S, A178N
PV6:262–289 E262T, T270D, S276G, G277N,
T280S, G283A, N289H
PV6:345–348 T345S, T346K, S348A
PV6:433,438 P433Q, N438D
PV6:262–289,345–348 E262T, T270D, S276G, G277N,
T280S, G283A, N289H, and T345S,
T346K, S348A
Note. The L1 genes of HPV6 and HPV11 were originally isolated from
linical sources. Substitutions into the HPV6 L1 gene were selected
tilizing the naturally occurring residue in the HPV11 L1 sequence, after
he two L1 genes were aligned to maximize homology. The L1 proteins
f HPV6 and HPV11 are 500 and 501 amino acids in length, respec-
ively. To maximize alignment, a single residue gap is introduced into
he HPV6 L1 sequence after residue 131, resulting in 38 residue differ-
nces between the aligned sequences. This offsets numbering C-
erminal to residue 131 by 1. For example, HPV6 L1 residues 345–348
orrespond to HPV11 L1 residues 346–349.H11.G131S.G3 was evaluated (Fig. 2). mAbs H6.C6 and
H11.B2 were included in the assays as controls. H6.C6
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240 LUDMERER ET AL.recognizes a linear epitope common to both HPV6 and
11; hence its binding is a measure of the relative
amounts of L1 among the different preparations. H11.B2
maps to G131Y132 of HPV11 L1 and should not bind to any
f the HPV6 VLP mutants (Ludmerer et al., 1996).
H11.H3 and H11.G131S.G3 bound HPV6:345–348 VLPs,
hich harbor three HPV11-like substitutions between L1
esidues 345 and 348. For both mAbs, binding was com-
ensurate with that to prototype HPV11 VLPs. This result
learly defines the H11.H3 binding site suggested in an
arlier study and is the first description of an HPV
pitope that encompasses residues from this region (Ro-
en et al., 1997; White et al., 1999). Furthermore, it is
nteresting to note that the antibodies that recognize this
egion were generated by two different approaches:
11.H3 by immunization with prototype HPV11 virions
nd H11.G131S.G3 by immunization with mutant VLPs.
A surprise came when the binding of these mAbs was
ssessed for the other mutant VLPs. Whereas H11.H3
ound only HPV6:345–348 VLPs, H11.G131S.G3 bound
ot only HPV6:345–348 VLPs but also bound HPV6:262–
89 VLPs, a mutant that contains seven 11-like substitu-
ions (Fig. 2). Moreover, the binding to HPV6:262–289
LPs was commensurate with the binding to prototype
PV11 VLPs. Although the binding of several HPV VLP-
ependent antibodies has been shown to be influenced
y residues well separated from one another on the
inear sequence, this is the first example of substitutions
FIG. 2. Three substitutions into the HPV6 L1 sequence redirect
binding of HPV11-specific neutralizing mAbs. A set of five HPV6 L1
mutants that harbor multiple, clustered, HPV11-like substitutions at
distinct regions of L1 were constructed and expressed in Sf9 cells as
described in the text. VLPs from clone HPV6:345–348, which harbor
three HPV11-like substitutions, bind HPV11-specific mAbs H11.H3 and
H11.G131S.G3. H11.G131S.G3 also binds VLPs expressed from mutant
HPV6:262–289, a mutant that harbors seven HPV11-like substitutions.
H6.C6 binds both native and denatured VLPs and is a measure of the
total L1 produced in the Sf9 cells. mAbs, used as dilutions of ascites
stock, are indicated. Antibody binding to an equal volume of extract
from nontransfected Sf9 cells is shown as a dashed line.t either of two distinct sites on HPV VLPs conferring
rototypic levels of binding. The integrity of the HPV6-likeharacter of the mutant VLPs was confirmed by the
inding of HPV6-specific VLP-dependent mAb H6.M48
Fig. 4; additional data not shown). H6.M48 binds all the
PV6 mutants, thus demonstrating that VLPs generated
y each of the mutant L1s still retain 6-like character.
LPs from three other HPV6 L1 mutants all failed to bind
11.H3 and H11.G131S.G3 (data from one mutant, HPV6:
69–178, are presented as representative of the three).
pecificity of transfer is also demonstrated by the lack of
11.B2 binding to VLPs produced by any of the mutants.
HPV6 L1 double-mutant HPV6:262–289,345–348,
hich contains residue substitutions at both
11.G131S.G3 binding sites, was constructed to deter-
ine whether stronger binding results from the presence
f both sites (Fig. 3). Within the limits of an end-point
LISA, the binding of the double-mutant was equivalent
o that of either single-mutant. To confirm and extend
hese observations, we titrated the antibodies against
he mutant VLPs (Table 4). The results showed that
pproximately the same concentrations of mAb
11.G131S.G3 produced half-maximal binding with VLPs
f either of the single-mutants or with the double-mutant
Table 4). The data indicate that H11.G131S.G3 forms a
table binding interaction through substitutions at either
f two distinct regions. The bulky size and lack of mat-
ration of mAb H11.G131S.G3 (IgM, see Table 1) may
ause this unusual binding behavior. For H11.H3, the
oncentrations necessary to achieve half-maximal bind-
ng with HPV11 prototype and HPV6:262–289,345–348
LPs were approximately the same, while about a five-
old higher concentration was required for HPV6:345–
FIG. 3. H11.G131S.G3 binds HPV6 VLPs that harbor HPV11-like sub-
stitutions at two distinct regions. Double-mutant HPV6:262–289,345–
348 was constructed and VLPs produced in Sf9 cells to assess whether
they will support a higher level of H11.G131S.G3 binding than VLPs
produced from either single mutant. H6.C6 is a measure of the total L1
produced by the Sf9 cells because it binds both native and denatured
VLPs. The relative signal intensity of H11.G131S.G3 to H6.C6 is roughly
equivalent with VLPs of either single-mutant or the double-mutant.
mAbs, used as dilutions of ascites stock, are indicated. Binding to an
equal volume of nontransfected Sf9 cell extract is shown as a dashed
line.
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241NEUTRALIZING mAbs GENERATED AGAINST HPV11 MUTANT VLPs348 VLPs. However, all these concentrations were ap-
proximately five orders of magnitude lower than the con-
centration required for half-maximal binding with HPV6:
262–289 VLPs. This suggests that a strong interaction
occurs between H11.H3 and residues 345–348 and that it
may be further stabilized by residues within the 262–289
region.
Two regions of HPV11 VLPs are required to establish
strong binding of mAbs H11.G131S.I1 and H11.G131S.K5.
H11.G131S.I1 and H11.G131S.K5 were also found to neu-
tralize virus; therefore it was of interest to map their
binding sites (Fig. 4). Both showed strong binding to
VLPs from the double-mutant HPV6:262–289,345–348,
and somewhat weaker binding to HPV6:262–289 VLPs
(compare the relative binding of H11.G131.I1 or
H11.G131.K5 to H6.C6 for the double-mutant versus sin-
gle-mutant HPV6:262–289). This suggests that it binds
principally to the 262–289 region, but that binding is
T
Antibody Titration Determines the Concen
VLP H11.H3
HPV11 prototype 5.0 3 106
HPV6:262–289,345–348 6.0 3 106
HPV6:262–289 ,1.0 3 101
HPV6:345–348 1.1 3 106
Note. Binding of mAbs to HPV11 VLPs and HPV6 mutant VLPs was
Binding was quantitated with alkaline phosphatase-conjugated seconda
observed.
FIG. 4. Neutralizing mAbs HPV11.G131S.I1 and H11.G131S.K5 bind
HPV6:262–289 VLPs. 1 mg of CsCl-banded VLPs assembled from
PV11, HPV6, and HPV6 mutants was immobilized and binding of
11.G131S.I1 and H11.G131S.K5 to the VLPs in an ELISA was evaluated
s described in the text. A 1:50 dilution of mAb produced in tissue
ulture supernatant was used per assay. Binding was observed to
utant HPV6:262–289 VLPs, but not to HPV6:345–348 VLPs or other
utant VLPs that were assayed but not shown. Binding of both anti-odies was also observed to VLPs from double-mutant HPV6:262–
89,345–348.influenced by residues from the other region.
H11.G131S.C2, a weak neutralizer, did not bind to any of
the mutants, indicating that either it binds a region of
VLPs not evaluated in this scan or its binding requires
additional HPV11-specific residues (N. D. Christensen,
unpublished observations).
In titration experiments, the concentration of
H11.G131S.I1 required to achieve half-maximal binding
was about 10-fold higher for HPV6:262–289,345–348
VLPs than for prototype HPV11 VLPs. For the single-
mutant HPV6:262–289, the concentration required was
about 1000-fold higher than that for prototype (100-fold
higher than for the double-mutant); for the other single-
mutant HPV6:345–348, the concentration of H11.G131S.I1
needed for half-maximal binding was four orders of
magnitude higher than for prototype HPV11. For
H11.G131S.K5, the half-maximal binding concentration
was approximately the same for either HPV11 prototype
or double-mutant HPV6:262–289,345–348 VLPs. Half-
maximal binding to single-mutant HPV6:262–289 re-
quired a concentration approximately 2.4-fold higher
than for HPV11 or HPV6:262–289,345–348 VLPs, and
binding of H11.G131S.K5 to single-mutant HPV6:345–348
was virtually undetectable. The results are consistent
with the end-point ELISA data of Fig. 4 and demonstrate
that the binding of mAbs H11.G131S.I1 and H11.G131S.K5
is principally centered at the 262–289 region, but that
these interactions are strengthened by residues from the
345–348 region.
DISCUSSION
An important observation from this set of studies is the
definition of L1 residues 346–349 as a neutralizing do-
main for HPV11. These residues are principally respon-
sible for type-specific binding of H11.H3 and contribute to
the binding of the other three mAbs evaluated in this
work. These results now identify a second region of
HPV11 VLPs capable of eliciting neutralizing responses,
the other being a linear stretch centered at residues
131–132. These two regions, 131–132 and 346–349, are
to Achieve Half-Maximal Binding to VLPs
31S.G3 H11.G131S.I1 H11.G131S.K5
103 2.4 3 106 1.2 3 102
103 1.6 3 105 0.9 3 102
103 2.0 3 103 5.0 3 101
103 1.0 3 102 ,1.0 3 100
ined by ELISA over a range of dilutions of stock antibody solutions.
body. The values given are the dilutions at which half-maximal A410 wasABLE 4
tration
H11.G1
1.7 3
2.3 3
3.0 3
3.0 3
determperhaps the dominant sites of HPV11 L1 in eliciting
neutralizing responses; mAbs that bind HPV11 VLPs at
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242 LUDMERER ET AL.other regions tend to have weaker or even no neutraliz-
ing activity. For example, mAb H11.A3.2, generated
against HPV11 virions, does not neutralize this virus in
the xenograph assay and its binding is not affected by
mutations within either of these regions. (Preliminary
studies place a critical portion of its binding site within
the first 60 residues; N. D. Christensen, S. W. Ludmerer,
and W. L. McClements, unpublished observations.) Nei-
ther region 131–132 nor region 346–349 has yet to be
defined as neutralizing in antibody mapping studies of
other HPV types. Neutralizing mAbs that are cross-reac-
tive with HPV types 6 and 11 have also been reported
and may identify additional neutralizing sites (Chris-
tensen et al., 1996c).
Another important observation is that diverged L1 res-
idues between 263 and 290 also confer type-specific
binding to HPV11 VLP mAbs. Previous studies have
shown that HPV16 L1 residues 269–284 form a linear
epitope that induces an HPV16-specific response useful
in the detection of this virus in human biopsy material
(Cason et al., 1989). More recently it has also been
shown that binding of mAb H16.E70, a type-specific,
neutralizing, VLP-dependent mAb, is dependent upon L1
residues A266 and S282 (Roden et al., 1996, 1997; White et
al., 1998, 1999). Due to the overall high level of homology
among HPV L1 sequences, the regions defined by
HPV16 L1 residues 266–282 and by HPV11 L1 residues
263–290 would be expected to be positioned similarly in
assembled VLPs. Thus we now see examples of mAbs
that while restricted in binding to distinct HPV VLP types,
are, nonetheless, likely to bind similar regions of the
respective capsids. Because the 346–349 region influ-
ences binding for all the mAbs discussed in this work,
however, we cannot at present conclude that neutraliza-
tion of HPV11 can occur through antibody binding solely
at the 263–290 region.
The mAbs analyzed in this work also illustrate a com-
plex association of two distinct regions of HPV11 L1.
Amino acids 263–290 and 346–349 are separated by
over 60 residues and are not likely to constitute a single
continuous binding site. The binding of mAbs
H11.G131S.I1 and H11.G131S.K5 is centered at region
263–290 and stabilized by residues 346–349. Conversely,
the binding of H11.H3 is strongly centered at region
346–346 yet is strengthened by residues 263–290. We
infer from the data that the two regions are in close
proximity within assembled particles, influencing subtle
conformational features of each other. Depending upon
which L1 residues mediate contact with a particular
antibody, binding may result from contact with either
region or with a feature generated only from the close
placement of both regions within assembled particles. It
has been demonstrated that mAb H11.H3 binds subpar-
ticle capsomers in addition to fully assembled VLPs
(Rose et al., 1998). It would be interesting to evaluate
whether the binding of mAbs H11.G131S.I1 and
A
bH11.G131S.K5 actually results from intercapsomeric con-
tacts at these two regions. Competition measurements
are not likely to be informative in that steric hindrance
can cause apparent binding competition between anti-
bodies known to bind discrete VLP regions (Christensen
et al., 1994, 1995b). It is also possible that mAb binding
actually occurs at a different region of the VLP that
becomes structurally altered by these substitutions. A
papillomavirus crystal structure would greatly increase
our understanding of how these different antibody inter-
actions may occur.
H11.G131S.G3 provides a unique tool to address
whether both regions 263–290 and 346–349 elicit neu-
tralizing responses and, if so, whether they are of similar
or different strengths. This question is intriguing in that,
as mentioned above, mAb H16.E70 neutralizes HPV16
infectivity in an in vitro assay, and its binding is partially
conferred by HPV16 L1 residues 266–282 (Roden et al.,
1996, 1997; White et al., 1998, 1999). H11.G131S.G3 can
stably bind HPV6 L1 mutants at either site, and the
presence of both binding sites (as in the HPV6 double-
mutant) offers little binding advantage over that to either
of the individual sites alone. Neutralization of HPV11
infectivity through H11.G131S.G3 binding at the 263–290
region would be a demonstration that neutralization of
distinct HPV types can occur through antibody binding to
diverged amino acid stretches located at near-equivalent
positions of the capsid. An adaptation of the pseudotype
infectivity assay to HPV6 VLPs (Kawana et al., 1998;
Roden et al., 1996; White et al., 1998; Zhao et al., 1998)
will facilitate this experiment.
MATERIALS AND METHODS
Generation of mAbs against G131S substituted HPV11
VLPs. mAbs reactive to HPV11:G131S VLPs were pre-
pared as previously described (Christensen et al., 1994,
1996a). Briefly, recombinant baculovirus-induced HPV11:
G131S VLPs were purified from infected Sf9 cells by CsCl
banding and used as immunogen. VLPs (100 mg per
ouse) were mixed with complete Freund’s adjuvant and
njected subcutaneously. Two weeks after immuniza-
ions, mice were sacrificed, and draining lymph node and
pleens were removed for fusion with P3X63–Ag8.653
ouse myeloma fusion partner cells. Hybridoma super-
atants were screened against HPV11:G131S VLPs and
ositive wells were cloned and retested. Results for 10 of
4 new mAbs are discussed in this work; 3 of the mAbs
ere selected for mapping studies. All mAbs utilized in
hese studies are listed in Table 5.
HPV11 in vitro neutralization assay. HPV11 neutraliza-
ion was tested using the in vitro neutralization assay as
reviously described (Smith et al., 1993, 1995) with some
odifications described below. Cell cultures of human
431 cells were grown in DMEM containing 10% fetal
ovine serum, penicillin/streptomycin, NaHCO3, HEPES,
c
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overnight incubation and cell attachment, aliquots of
HPV11 (5 3 103 dilution of extract from experimental
ondylomas from athymic mice for low viral input, 1 3
03 dilution for high viral input (Kreider et al., 1985) in
0-ml volumes were incubated with 40 ml of mAb cell
culture supernatant for 1 h at 37°C and then added in a
1-ml volume to replicate cultures of A431 cells. After 3
days of further growth, the cells were harvested using
Trizol reagent (Gibco BRL) and then processed for RNA
purification and RT-PCR as described below. Control
cultures contained either no virus or virus-infected cul-
tures without mAb supernatant.
Primers spanning a major splice junction site of the
most abundant HPV11 transcript(s) (Nasseri et al., 1987)
were prepared as described below. b-actin primers were
dentical to those described by Smith et al. (1993, 1995).
All primers are presented as 59 to 39. Optimized primer
selection for HPV11 cDNA amplification was based on
published sequences and theoretical considerations
(Myers et al., 1994; Rychlik and White, 1993).
(1) RT step: The RT reactions were primed using the
downstream reverse primers 3684GCCCAATGCCACGTT-
GAAGA3665 for HPV11 truncated cDNA and 1036GGAG-
CAATGATCTTGATCTTC1016 for b-actin cDNA.
(2) First PCR step: The first PCR amplification used the
following primers: HPV11 upstream-outside primer
778GCTGGGCACACTAAATATTGT798; HPV11 downstream-
outside primer 3684GCCCAATGCCACGTTGAAGA3665;
b-actin upstream-outside primer 395GATGACCCAGAT-
ATGTTTT414; and b-actin downstream-outside primer
1036GGAGCAATGATCTTGATCTTC1016.
(3) Second PCR step: The second PCR amplification
sed inside (nested) primers; HPV11 upstream-inside
808 828
T
mAbs Utili
mAb Type
H11.A3.2 IgG 2a
H11.B2 IgG 2b
H11.H3 IgG 2b
H6.C6 IgG 2a
H6.M48 IgG 1
H11.G131S.A10 IgG1
H11.G131S.B8 IgG 2a
H11.G131S.C2 IgG 1
H11.G131S.D2 IgG 2a
H11.G131S.E38 IgA
H11.G131S.F6 IgG 2b
H11.G131S.G3 IgM
H11.G131S.H5 IgG 1
H11.G131S.I1 IgG 1
H11.G131S.K5 IgG 2arimer CTGCGCACCAAAACCATAACA ; HPV11
ownstream-inside primer 3578TAGGCGTAGCTGCACT-GTGA3559; b-actin upstream-inside primer 423AACAC-
CCCAGCCATGTACGTTG444; and b-actin downstream-in-
side primer 852ACTCCATGCCCAGGAAGGAAGG831.
RT-PCR procedures. Cell cultures were lysed in 1 ml
Trizol Reagent (Gibco BRL), and total cellular RNA was
prepared by standard procedures. The RNA was sus-
pended in 30 ml of diethylpyrocarbonate-treated distilled
H2O, and aliquots were analyzed by agarose gel electro-
horesis and quantified spectrophotometrically (A260).
cDNA synthesis was conducted according to the manu-
facturer’s instructions (GeneAmp RNA PCR kit from Per-
kin–Elmer). RNA (1 ml) obtained from cultures of virus-
infected and uninfected A431 cells was placed into a
microfuge containing a 2.5 mM concentration of specific
rimer (HPV11 or b-actin), RT buffer, 5 mM MgCl2, DEPC-
treated distilled water, 1 mM each of dGTP, dATP, dTTP,
and dCTP, RNase inhibitor (1 ml of 1 U/ml) and 1 ml (2.5
U/ml) of MuLV reverse transcriptase in a total volume of
0 ml, and the contents were mixed gently. The reaction
mixture was then incubated at 37°C for 1 h. The cDNA
preparations were used directly in the PCRs. PCRs were
conducted according to the manufacturer’s instructions
(GeneAmp RNA PCR kit from Perkin–Elmer). A master
mix containing 2 mM MgCl2, 13 PCR buffer, AmpliTaq
NA polymerase (0.5 ml of 2.5 U/100 ml), and DEPC-
treated distilled water, and a 0.1 mM concentration of
ach of the upstream-outside and downstream-outside
rimers for HPV11 and b-actin in an 80-ml volume. To this
as added the 20 ml RT reaction contents. The tubes
ere placed into a thermocycler and the following cy-
ling parameters were used: denaturation for 1 min at
5°C, annealing at 60°C for 1 min, and polymerization at
2°C for 1 min. The number of cycles was set at 30. For
he second round of PCR amplification, 5 ml of the above
This Work
munogen Source
virions Christensen et al. (1990)
virions Christensen et al. (1990)
virions Christensen et al. (1990)
VLPs Christensen et al. (1996c)
VLPs Christensen et al. (1996c)
:G131S VLPs This work
:G131S VLPs This work
:G131S VLPs This work
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PCR products were separated on an ethidium bromide-
stained agarose gel for scanning and for photography
using an ITTI image analysis system.
Generation of L1 mutants and VLP ELISAs. The L1
genes of HPV6 and HPV11 were cloned from clinical
isolates as previously described (Dartmann et al., 1986;
Hofmann et al., 1995; Ludmerer et al., 1996; Schwarz et
al., 1983) and subcloned into pBlueScript (Stratagene, La
Jolla, CA) to generate single-stranded DNA templates for
mutagenesis. L1 mutants were generated by site-di-
rected mutagenesis using the Sculptor in vitro mutagen-
esis system (Amersham International), subcloned into
baculovirus transfer vector pVL1393 (Stratagene) for ex-
pression (Table 3), and verified by complete gene se-
quencing. L1 clones that harbor multiple clustered sub-
stitutions (no more than 10 residues separating any two
pairwise substitutions) are called single-mutants; an L1
clone that contains two sets of multiple substitutions,
separated by over 60 residues, is called a double-mu-
tant.
ELISAs were performed with VLPs expressed in trans-
fected Sf9 cells or utilizing CsCl-banded VLPs purified
from infected Sf9 cells. To express VLPs in transfected
Sf9 cells, 5 mg transfer vector plus 0.5 mg BaculoGold
NA was transfected into approximately 2 3 106 Sf9
ells using the BaculoGold Transfection System (Phar-
ingen) according to the manufacturer’s instructions.
ive to 6 days after transfection, the cells were harvested
nd disrupted by sonication. Lysates were cleared by
entrifugation and were assayed immediately or frozen
t 270°C for subsequent analysis. VLP-bearing and con-
rol (mock-transfected Sf9 cells) lysates were assayed in
uplicate by ELISA (in antibody excess) as described
reviously (Benincasa et al., 1996) except that detection
f HRP activity was with TMB (Pierce) stopped by addi-
ion of H2SO4 and quantitation was at 450 nm. ELISA with
sCl-banded VLPs utilized 1 mg protein/well; detection
was with alkaline phosphatase-conjugated secondary
antibody quantitated at 410 nm. Primary antibody for all
assays was prepared by diluting ascites fluid 105 for
6.M48, H6.J54, H6.C6, H11.B2, and H11.H3 or 103 for
11.G131S.G3, unless specified otherwise. Data pre-
ented in Figs. 2 and 3 are the average of duplicate
ssays performed at Merck Research Laboratories, West
oint; the results were confirmed by an independent trial
t Penn State University. Data presented in Fig. 4 and
ables 1 and 4 are the average of triplicate assays
erformed at Penn State University; results were con-
irmed in a separate trial at the same institution.
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